Show
Sort by
-
- Journal Article
- A1
- open access
Phase I dose‐escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
-
Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML : a retrospective study by the I-BFM Study Group
-
The genetic basis and cell of origin of mixed phenotype acute leukaemia
-
Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups
-
Genomic landscape of pediatric mixed phenotype acute leukemia
-
Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics
-
Collaborative efforts driving progress in pediatric acute myeloid leukemia
-
Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study
-
Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML : results from an international retrospective study by the International Berlin-Frankfurt-Münster study group
-
Results of a feasibility and phase II study on bortezomib (BTZ) in pediatric multiply relapsed of refractory acute lymphoblastic leukemia: complete hematological responses with a modestly intensive regimen including BTZ